Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 1, 2005

Influence of in vivo Hemoglobin Carbamylation on HbA1c Measurements by Various Methods

  • Abdelhalim Chachou , Christine Randoux , Hervé Millart , Jacques Chanard and Philippe Gillery
From the journal


Increased carbamylated hemoglobin formed in erythrocytes during uremia may interfere with Hba1c assays, but few studies compared directly both parameters. We measured carbamylated hemoglobin by HPLC in 45 non-diabetic uremic patients (16 with acute and two with chronic renal failure, 27 with transplant recipients) as 57.8 ± 22.3 μg carbamylvaline/g Hb (mean ± standard deviation) vs. 31.6 ± 5.1 in 15 controls (+83%, p < 0.001). In these samples, HbA1c was evaluated by three ion-exchange HPLC methods, 1: Diamat (BioRad), 2: A1c2.2 (Tosoh) and 3: HA8140 (Menarini), and one immunoassay method (Tinaquant II Roche). Whichever the method, mean HbA1c values obtained increased in patients with high (> 60 μg carbamylvaline/g Hb) vs. low (< 45) carbamylated hemoglobin values (+0.08 to 0.25% of total Hb), but differences were not significant. Minor peaks on the chromatograms were however increased in parallel to carbamylated hemoglobin. HbA1c values over 6% were found in 4, 1, 2 and 0 samples, with HPLC 1, 2, 3 and immunoassay, respectively. Fructosamine values were not significantly altered. Our results show that Hb adducts, whether due to carbamylation or to other chemical reactions, interfere to a variable extent with different HbA1c assay methods, and confirm that HbA1c values should be interpreted with caution in uremic patients.

Published Online: 2005-06-01
Published in Print: 2000-04-30

Copyright © 2000 by Walter de Gruyter GmbH & Co. KG

Downloaded on 26.3.2023 from
Scroll Up Arrow